IBD at the End of its First Century

List of Principal Authors. <strong>Section I: Aetiopathogenesis. 1.</strong> Susceptibility Genes for IBD; D. van Heel, et al. <strong>2.</strong> Interleukin-1 Beta Gene Polymorphisms as Genetic Markers in Perforating and Non-Perforating Crohn's Disease; A. Nemetz, et al. <strong>3.</strong> Genetic Determination and Susceptibility: Future Aspects; R.H. Duerr. <strong>4.</strong> Interactions Between Enteric Bacteria and the Immune System Which Determine Mucosal Homeostasis vs. Chronic Intestinal Inflammation: Lessons from Rodent Models; R.B. Sartor, C. Veltkamp. <strong>5.</strong> Gut Flora: Future Implications; R. Duchmann. <strong>6.</strong> Response and Non-Response in the Mucosal Immune System; W. Strober, et al. <strong>7.</strong> Immunotherapeutic Approaches in Inflammatory Bowel Diseases; M.F. Neurath, et al. <strong>8.</strong> Intestinal Epithelial Barrier Dysfunction; S.V. Sitaraman, et al. <strong>9.</strong> IL-10 Inhibits NF-kB by Distinct Mechanisms; A.J.G. Schottelius, et al. <strong>10.</strong> Future Ways to Study Epithelial Cell Functions; G. Rogler. <strong>11.</strong> Regulation of Intestinal Crypt Cell Apoptosis in the Murine Acute Graft-versus-Host Disease; E. Stüber, et al. <strong>12.</strong> Apoptosis and Mucosal Lymphocytes: Defective Mucosal Lymphocyte Apoptosis is Associated with Inflammation; M. Boirivant, et al. <strong>13.</strong> Regulation of Intestinal Epithelial Wound Healing; M.N. Göke, D.K. Podolsky. <strong>14.</strong> Myofibroblasts and Epithelial Repair in the Intestinal Mucosa; M.N. Göke, D.K. Podolsky. <strong>15.</strong> Etiopathogenesis 1999 - How to Put it All Together; C.O. Elson, et al. <strong>Section II: Clinical</strong> <strong>Approach and Treatment. 16.</strong> The Influence of 20th Century Biomedical Thought on the Origins of IBD Therapy; J.B. Kirsner. <strong>17.</strong> Differentiation and Subgrouping of IBD: State of the Art; P. Rugeerts, et al. <strong>18.</strong> Differentiation and Subgrouping of Crohn's Disease; G. Rocca, et al. <strong>19.</strong> Do Subgroups of Crohn's Disease Matter for Future Patient Care? C. Gasche. <strong>20.</strong> Treatment of Active, Severe and Refractory Ulcerative Colitis: State of the Art; S.B. Hanauer. <strong>21.</strong> Treatment of active, severe and refractory ulcerative colitis: new therapeutic approaches, unpublished data; H. Herfarth. <strong>22.</strong> Cyclosporin for Corticosteroid-Refractory Ulcerative Colitis. Refinement of Current Treatment Modalities; G.C. Actis, et al. <strong>23.</strong> Two Decades of Restorative Proctocolectomy: Laudation or Requiem for the Ileoanal Pouch Procedure? C. Herfarth, et al. <strong>24.</strong> Risk of Dysplasia in Long-Term Ileal Pouches or Pouches with Chronic Pouchitis; M. Thompson-Fawcett. <strong>25.</strong> Improving the Long-Term Outcome of Surgery: The Future; R.S. McLeod. <strong>26.</strong> Azathioprine Metabolism in IBD: Correlation with Efficacy and Toxicity; C. Cuffari. <strong>27.</strong> Steriod Dependent and Refradctory Disease: State of the Art; D.H. Present. <strong>28.</strong> Thalidomide Therapy: History, Pharmacology and Consideration as a Treatment for Crohn's Disease; E.D. Ehrenpreis, et al. <strong>29.</strong> Maintenance of Remission in Ulcerative Colitis and Crohn's Disease; L.R. Sutherland. <strong>30.</strong> Remission Maintenance in UC and CD: Unpublished Data; P. Gionchetti, et al. <strong>31.</strong> Experimental Treatments in IBD &endash; Are Too Many and Do We Have the Right Targets? J. Sch&ouml;lmerich. <strong>32.</strong> Patient Education in Patients with Inflammatory Bowel Disease; N. Bregenzer, et al. <strong>33.</strong> Supportive Care in Inflammatory Bowel Disease; E.J. Irvine. <strong>34.</strong> How to Put it All together &endash; Visions for the Second Century; W.J. Sandborn. Index.